⦁ We are an oncology-focused biotech company.
⦁ Using VHH antibody as a building block, we are developing novel, next generation bispecific antibody drugs to improve clinical outcome for cancer patients with resistance and/or unmet medical needs.
⦁ We focus on both immunotherapy and targeted-therapy with emphasize on bispecific antibody drug conjugates.
